Is $GERN a stock for "Strong Holders"?Geron CorporationBATS:GERNmyParadoxeOr is it just another stock whose value will be wiped out in the next few quarters, and the company will simply lose its listing on the Nasdaq? Investors are likely to get an answer to this question today, before the market opens, when GERN reports its quarterly earnings. The company has an approved drug and has already begun commercialization, with a promising start. Last quarter, the company generated $28 million in revenue, and this quarter, revenue is expected to reach $61.8 million. The company has already achieved positive gross margins, and I expect them to improve significantly from the current 27% in the last quarter. Operating expenses are close to $30 million per quarter, so we can expect a quick path to operating profitability. Invested capital is around $135 million, which means that with an operating profit of $10 million per quarter, we could see interesting returns on invested capital. The company is led by John A. Scarlett, M.D., who previously worked at CTMX for six years, during which the company lost about 90% of its value. There is some positive news regarding European approval: "The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion." A decision is expected in the coming months, if not days, which should serve as a strong catalyst for the stock price. The market valuation has dropped to $1.4 billion, despite having an FDA-approved drug in the U.S. Cash reserves will be important as they indicate how much time the company has to develop without diluting its capital. In the last report, cash and short-term investments totaled $339 million, and on November 7, the company announced securing $250 million in funding, with the potential to increase it to $375 million. As a result, the company has $589 million in cash reserves minus operating cash flow. How much will remain in the coffers? The company should have enough cash for more than 12 months of successful operations, operational efficiency is improving, we are awaiting European approval, and only the quality of management raises doubts. But do these doubts really hold weight given the current trajectory? There are only a few hours left until the earnings report is released. Let's see what awaits us. Strong Holders Profiting From Strength 📉✊📈